Shares in Oxford Biomedica shares rose 6% today after it reported half-year results.
The listed cell and gene therapy pioneer, which is targeting profitability, reiterated previous full-year guidance as it reported a 9% increase in revenues to £79.8 million for the six months ended 30th June 2026.
With 17 new clients signed in H1 2026 – more than 30% above the total number signed during FY 2025 – it said adjusted operating EBITDA improved to a £2.5m loss from £3.9m in H1 2025, driven by stronger revenues and continued cost discipline.
With a mission to enable its clients to deliver life changing therapies to patients around the world, OXB has 30 years of experience in viral vectors – the driving force behind the majority of cell and gene therapies.
It collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types.
The company has an ambition to reach revenues of £500m by 2030, with long-term EBITDA margins approaching 30%.
“OXB delivered a strong first half commercially, with record new client wins, an increase in programmes to 59 and continued revenue growth,” said CEO Dr Frank Mathias.
“Importantly, our Durham, NC site is now operationally ready and serving clients, with GMP manufacturing capabilities online and the first GMP run completed.
“Alongside continued progress across our UK, France and Bedford, MA sites, this materially strengthens our global, multi-vector CDMO network and supports confidence in our revenue outlook.
“There is a clear demand for OXB’s differentiated capabilities and we believe we are increasingly well positioned to benefit from the maturation of the cell and gene therapy market. Our operational focus remains on disciplined execution and cost control as we drive utilisation and progress towards our 2030 revenue and sustainable profitability ambitions.”